

Simone Krebs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7137804/publications.pdf>

Version: 2024-02-01

25
papers

685
citations

840776

11
h-index

642732

23
g-index

27
all docs

27
docs citations

27
times ranked

1106
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1248-1252.	5.0	197
2	Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13R α 2-positive Glioma. <i>Molecular Therapy</i> , 2016, 24, 354-363.	8.2	72
3	Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan. <i>Clinical Cancer Research</i> , 2019, 25, 6939-6947.	7.0	69
4	T cells redirected to interleukin-13R α 2 with interleukin-13 mutein α 2 chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13R α 1. <i>Cytotherapy</i> , 2014, 16, 1121-1131.	0.7	68
5	Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 677-685.	6.4	44
6	IDEAL-IQ in an oncologic population: meeting the challenge of concomitant liver fat and liver iron. <i>Cancer Imaging</i> , 2018, 18, 51.	2.8	36
7	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1894-1900.	5.0	36
8	Pharmacokinetic Assessment of ¹⁸ F-(2 <i>S</i> ,4 <i>R</i>)-4-Fluoroglutamine in Patients with Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 357-366.	5.0	23
9	Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3047-3057.	6.4	19
10	Genetically Modified T Cells to Target Glioblastoma. <i>Frontiers in Oncology</i> , 2013, 3, 322.	2.8	16
11	MRI liver fat quantification in an oncologic population: the added value of complex chemical shift-encoded MRI. <i>Clinical Imaging</i> , 2018, 52, 193-199.	1.5	14
12	Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. <i>Annals of Lymphoma</i> , 2021, 5, 15-15.	4.5	13
13	Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction. <i>Journal of Nuclear Medicine</i> , 2019, 60, 879-881.	5.0	11
14	IgG4-Related Kidney Disease in a Patient With History of Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e388-e389.	1.3	10
15	Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3940-3950.	6.4	8
16	Lower-Extremity Pseudomyogenic Hemangioendothelioma on Bone Scintigraphy and PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, 383-385.	1.3	7
17	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage—Case Report. <i>Frontiers in Oncology</i> , 2017, 7, 284.	2.8	7
18	CAR Chase: Where Do Engineered Cells Go in Humans?. <i>Frontiers in Oncology</i> , 2020, 10, 577773.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Patient Size-Dependent Dosimetry Methodology Applied to ¹⁸ F-FDG Using New ICRP Mesh Phantoms. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1805-1814.	5.0	7
20	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. <i>Bioconjugate Chemistry</i> , 2021, 32, 649-654.	3.6	6
21	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1580-1587.	5.0	5
22	[⁸⁹ Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 783-785.	6.4	4
23	Value of [¹⁸ F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa050.	0.7	3
24	Cell carriers to attack glioma. <i>Cytotherapy</i> , 2014, 16, 871-872.	0.7	0
25	IM-02 * A scFv-BASED CAR TO REDIRECT T CELLS TO IL13R ⁺ -POSITIVE PEDIATRIC GLIOMA. <i>Neuro-Oncology</i> , 2015, 17, iii15-iii15.	1.2	0